Login to Your Account

NicOx Takes Hit On Data, Calls For Inquiry Into Stock Movement

By James Etheridge

Wednesday, February 26, 2003
PARIS - The share price of NicOx SA on the Nouveau Marché in Paris plummeted by more than 83 percent last week after AstraZeneca plc issued a statement in the names of both companies announcing that the recently completed Phase II trial of a drug candidate they are developing did not attain its primary therapeutic objective. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription